Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-NeoBOMB1 and 68Ga-PSMA R2 PET/MRI in Recurrent Prostate Cancer
NCT03698370Phase 2Completed
- Sponsor
- Andrei Iagaru
- Start
- Dec 2020
- Primary completion
- Feb 2022
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of gallium Ga 68 DOTA-NeoBOMB1 in prostate cancer (PCa), sponsored by Andrei Iagaru. Started Dec 2020; status: completed.
02
Drugs
gallium Ga 68 DOTA-NeoBOMB1
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03698370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03698370.